Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37.521
Filtrar
1.
J Ethnopharmacol ; 336: 118742, 2025 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-39197806

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: In traditional Persian medicine (TPM), people often use herbal infusions as a dosage form to treat diseases related to hyperglycemia, known as 'dam-kardeh'. Traditionally, herbal preparations of Eryngium bungei Boiss. (E. b), Tragopogon buphthalmoides (DC.) Boiss. (T. b), Salvia hydrangea DC. ex Benth. (S. h), and Juniperus polycarpos K. Koch. (J. p) are used to manage diabetes in Iran. However, there is no evidence of their effectiveness in controlling glucose levels and their mechanisms remain unclear. AIM OF THE STUDY: This study aimed to investigate whether traditional doses of plant infusions can have hypoglycemic and/or anti-hyperglycemic effects during fasting and/or postprandial states and establish the basis for future research on their potential mechanisms of action. MATERIALS AND METHODS: The effects of traditional doses of herbal extracts on blood glucose levels in STZ-NA-induced hyperglycemic rats were investigated in 2-h acute tests during fasting and postprandial states (with a glucose load). In addition, the potential inhibitory effect in vitro of enzymes involved in relevant pathways, such as gluconeogenesis (fructose-1,6-bisphosphatase, FBPase and glucose-6-phosphatase, G6Pase), carbohydrate breakdown (intestinal α-glucosidases), and insulin sensitivity (protein tyrosine phosphatase 1B, PTP-1B) was evaluated. Acute toxicity tests were carried out and HPLC-SQ-TOF was used to analyze the chemical profiles of the plant extracts. RESULTS: In the fasting state, T. b, S. h, and E. b were as effective as glibenclamide in lowering blood glucose levels in hyperglycemic rats. Moreover, all three suppressed G6Pase and FBPase enzymatic activity by 90-97% and 80-91%, respectively. On the other hand, significant postprandial hypoglycemic efficacy was observed for E. b, S. h, and T. b. Based on the AUC values, T. b caused a reduction comparable to the therapeutic efficacy of repaglinide. When investigating the possible mechanisms of action involved in this activity, E. b, S. h, and T. b showed significant inhibition of PTP-1B in vitro (>70%). Finally, all plant extracts showed no signs of acute toxicity. Several compounds that may contribute to biological activities were identified, including phenolic acids and flavonoid glycosides. CONCLUSIONS: The present study supports the traditional use of T. b, E. b and S. h for the control of diabetes in the fasting and postprandial state. Moreover, these plants were found to be rich in bioactive compounds with hypoglycemic and antihyperglycemic activities. On the other hand, J. p, showed a modest effect only in the fasting state and after 90 min. Further studies are needed to expand these results by analyzing the chemical composition and using complementary experimental models.


Assuntos
Glicemia , Diabetes Mellitus Experimental , Jejum , Hipoglicemiantes , Extratos Vegetais , Período Pós-Prandial , Animais , Hipoglicemiantes/farmacologia , Extratos Vegetais/farmacologia , Extratos Vegetais/administração & dosagem , Extratos Vegetais/química , Glicemia/efeitos dos fármacos , Glicemia/metabolismo , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/sangue , Masculino , Irã (Geográfico) , Ratos , Medicina Persa , Ratos Wistar , Hiperglicemia/tratamento farmacológico , Plantas Medicinais/química , Estreptozocina , Juniperus/química
2.
Arch. argent. pediatr ; 122(5): e202310168, oct. 2024.
Artigo em Inglês, Espanhol | LILACS, BINACIS | ID: biblio-1571504

RESUMO

Los postbióticos fueron definidos en 2021 por la Asociación Científica Internacional de Probióticos y Prebióticos (ISAPP) como "una preparación de microorganismos inanimados y/o sus componentes celulares capaces de conferir un efecto benéfico al hospedador". El campo de los postbióticos es un área nueva dentro de la familia de los bióticos; se han desarrollado ya numerosos productos con aplicaciones clínicas, como la estimulación inmunológica, el manejo de diarreas en niños y adultos, el abordaje del intestino irritable, además de tres fórmulas infantiles. En particular, las fórmulas infantiles con postbióticos obtenidos a partir de la fermentación de la leche con Bifidobacterium breve C50 y Streptococcus thermophilus O65, y sus metabolitos, incluido el oligosacárido 3'-GL, han demostrado seguridad y contribución al desarrollo de la microbiota intestinal y el sistema inmune asociado al intestino. Estas modificaciones contribuyen a la prevención y el manejo de los trastornos funcionales digestivos del lactante.


Postbiotics were defined in 2021 by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as a "preparation of inanimate microorganisms and/or their cellular components that confers a health benefit to the host." The field of postbiotics is a new area within the biotics family; numerous products have already been developed for clinical applications, such as immune stimulation, the management of diarrhea in children and adults, the management of irritable bowel syndrome, and 3 infant formulas. In particular, infant formulas with postbiotics obtained from milk fermented with Bifidobacterium breve C50 and Streptococcus thermophilus O65 ­and their metabolites­, including the oligosaccharide 3'-GL, have demonstrated to be safe and to contribute to the development of the gut microbiota and the gutassociated immune system. These modifications help to prevent and manage functional gastrointestinal disorders in infants.


Assuntos
Humanos , Lactente , Probióticos , Síndrome do Intestino Irritável/microbiologia , Síndrome do Intestino Irritável/terapia , Fórmulas Infantis , Streptococcus thermophilus , Diarreia/microbiologia , Diarreia/terapia , Prebióticos/administração & dosagem , Microbioma Gastrointestinal , Bifidobacterium breve , Gastroenteropatias/microbiologia , Gastroenteropatias/terapia
3.
J Anim Sci ; 1022024 Jan 03.
Artigo em Inglês | MEDLINE | ID: mdl-39367535

RESUMO

Tannins are phenolic compounds that provide benefits to ruminants due to their protein-binding affinities and antioxidant properties. However, tannins may also have negative orosensorial and postingestive effects that decrease feed intake. This study explored how lambs trade off the ingestion of crude protein (CP) with the ingestion of potentially beneficial and toxic condensed and hydrolyzable tannins, and the ensuing impacts on diet digestibility, animal performance, and blood parameters. Thirty-two lambs were housed in individual pens for 8 wk and had access to 2 isoenergetic diets that varied in the concentration of CP (High-high in protein [HP] or Low-least preferred [LP]) and the presence of a mix of condensed and hydrolyzable tannins (4% DM). Animals were assigned to 4 treatment groups (N = 8 lambs/group) and received a simultaneous offer of: HP and LP (Control); HP and LP + tannins (HP - LP+); HP+ tannins and LP (HP + LP-); and both HP and LP with tannins (HP + LP+). All lambs preferred HP over LP and they avoided tannins in the diets (P < 0.001). Dry matter and CP intake were the lowest in HP + LP- (P < 0.0001), and DMD did not differ between Control and the other groups (P > 0.05), but it was greater for HP - LP + (P < 0.0001). CP digestibility was greater for groups without tannins in HP (P < 0.0001), but average daily gain (ADG) did not differ among treatments (P > 0.05). No differences between Control and HP + LP + were found in plasma antioxidant activity, total phenolic concentration, or haptoglobin concentration (P > 0.05). Intake of tannins was HP + LP+ > HP + LP- > HP - LP + (P < 0.0001), and fecal excretion of nitrogen (N) was HP + LP+ > HP - LP+ = HP + LP- > Control (P < 0.05). In addition, intake of tannins with both diets reduced blood urea nitrogen (BUN) concentration relative to Control (P < 0.05), thus suggesting a shift in the partitioning of N excretion from urine to feces. In summary, lambs prioritized the selection of HP over LP, regardless of the presence of a tannin extract in either or both diets. Nevertheless, lambs modulated their tannin consumption as a function of the specific diet where the tannin extract was added, with increasing levels of intake as tannins were present in just LP, then in just HP, and finally in both diets. Dietary tannins did not constrain ADG and resulted in a shift in the partitioning of N excretion from urine to feces. Such shifts have been found to result in reduced production of environmental pollutants such as ammonia, nitrous oxide, and nitrates.


Tannins are plant chemicals that can provide benefits to ruminants due to their antioxidant activity and positive effects on nutrient uptake. However, tannins could also promote negative (i.e., toxic) effects on herbivores. This study explored how lambs build their diets when offered between 2 diets that varied in protein concentration (low or high), both with and without tannins (4%) and the ensuing consequences on diet digestibility, animal performance, and some blood parameters indicative of antioxidant activity and inflammation. All lambs preferred the high-over the low-protein diet, regardless of the inclusion of tannins in the diets. Digestibility of dry matter did not differ between lambs that had diet choices with or without tannins, and body weight gains were not different across all treatments. No differences were found among dietary treatment groups in blood antioxidant activity or indicators of inflammation. Tannin intake promoted a shift in the fate of nitrogen excretion from urine to feces, suggesting reductions in environmental pollutants such as ammonia, nitrous oxide, and nitrates. Thus, tannins did not promote negative impacts on animal performance with potential concomitant beneficial effects on the environment.


Assuntos
Ração Animal , Dieta , Proteínas Alimentares , Taninos , Animais , Taninos/farmacologia , Taninos/administração & dosagem , Taninos/metabolismo , Ração Animal/análise , Dieta/veterinária , Ovinos/fisiologia , Proteínas Alimentares/metabolismo , Digestão/efeitos dos fármacos , Masculino , Fenômenos Fisiológicos da Nutrição Animal
4.
Sci Rep ; 14(1): 23921, 2024 10 13.
Artigo em Inglês | MEDLINE | ID: mdl-39397094

RESUMO

Psychedelics have a complex history marked by traditional use among indigenous cultures, early scientific interest, and subsequent prohibition. Despite their classification as controlled substances, recent decades have witnessed a resurgence of research into their therapeutic potential for various mental health conditions. However, most studies have focused on controlled clinical settings, leaving a significant gap in understanding how these substances are used in naturalistic contexts, particularly in Latin America. This study investigates the regular use of macrodoses of psychedelics among Latin American adults. We aimed to characterize the sociodemographic profiles, consumption practices, and subjective effects experienced by individuals who use psychedelics regularly. Data were collected via an online survey from 4,270 participants across several Latin American countries. Results indicated a diverse user base with varied motivations, predominantly psychological and spiritual well-being. The most frequently used substance was psilocybin mushrooms, with significant associations found between demographic variables and specific psychedelics used. The study provides new insights into the naturalistic use of psychedelics in Latin America, highlighting the need for informed, safe, and legal use frameworks.


Assuntos
Alucinógenos , Humanos , Alucinógenos/administração & dosagem , Adulto , América Latina , Feminino , Masculino , Estudos Transversais , Pessoa de Meia-Idade , Adulto Jovem , Inquéritos e Questionários , Adolescente , Psilocibina/uso terapêutico , Psilocibina/administração & dosagem
5.
Eur J Orthop Surg Traumatol ; 34(7): 3789-3795, 2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39352525

RESUMO

PURPOSE: The objective of this study was to describe the use of retrograde gentamicin-coated tibial intramedullary nail (ETN PROtect™) in patients with tibial defects who required a tibiotalocalcaneal arthrodesis (TTC). METHODS: Consecutive series case review of seven men treated with TTC using retrograde PROtect™ between January 2018 and December 2023. The main outcomes evaluated were fracture union, complications, and the health-related quality of life using the EuroQol five-dimension three-level questionnaire (EQ-5D-3L). RESULTS: The mean age was 45.3 ± 8.0 years. Six patients had a clinical history of chronic osteomyelitis, and one case underwent TTC for congenital pseudoarthrosis. Fracture union was achieved in 5 of 7 patients between 4 and 11 months after surgery. Three patients developed complications; two patients had fistulas, and one had persistent pain. At the end of the follow-up, a median of 70 points (interquartile range: 60 to 90) on the EQ-5D-3L was reported. No complications directly attributed to the use of the PROtect™ were reported. CONCLUSION: TTC with retrograde PROtect™ is a prophylactic treatment option in patients with tibial defects treated with external fixation requiring a tibiotalar and subtalar arthrodesis. This novel use of PROtect™ allows simultaneous fixation of the tibiotalocalcaneal joint and protection of the regenerated bone, facilitating earlier rehabilitation in patients at high risk for postoperative infections.


Assuntos
Artrodese , Pinos Ortopédicos , Gentamicinas , Osteomielite , Tíbia , Humanos , Artrodese/métodos , Artrodese/instrumentação , Artrodese/efeitos adversos , Masculino , Gentamicinas/administração & dosagem , Gentamicinas/uso terapêutico , Pessoa de Meia-Idade , Tíbia/cirurgia , Adulto , Osteomielite/cirurgia , Osteomielite/etiologia , Osteomielite/prevenção & controle , Articulação do Tornozelo/cirurgia , Fixação Intramedular de Fraturas/instrumentação , Fixação Intramedular de Fraturas/métodos , Fixação Intramedular de Fraturas/efeitos adversos , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Pseudoartrose/cirurgia , Pseudoartrose/prevenção & controle , Pseudoartrose/etiologia , Qualidade de Vida , Calcâneo/cirurgia
6.
Curr Microbiol ; 81(11): 386, 2024 Oct 02.
Artigo em Inglês | MEDLINE | ID: mdl-39358608

RESUMO

High-density stress can lead to dysbiotic microbiota, affecting the organism's metabolic, and protective functions. Agavin is a fructan with prebiotic properties that regulate the gut microbiota by promoting the growth of beneficial bacteria. This study evaluated the effect of agavin on the gut microbiota using Next-Generation Sequencing (NGS) and its correlation with the growth parameters. Four groups of fish were fed different diets: a control diet (negative and positive control), without agavin supplementation, and two experimental diets supplemented with agavin at 20 g kg-1 and 40 g kg-1. Nile tilapias (1.04 g ± 0.01 g) were fed for 110 days. After 90 days of feeding, fish were subjected to high-density stress (63 kg m-3) for 20 days, except for the negative control. NGS detected 1579 different operational taxonomic units in the samples. In the correlation analysis of growth parameters, the families Vibrionaceae and Methyloligillaceae showed a positive correlation with fish growth parameters, these results may serve to know the relation of agavin and microbiota on the growth performance, as well as the metabolic activities of families in tilapia. Furthermore, high-density stress and agavin supplementation modify the gut microbiota in tilapia. At a low-density, supplementation with 20 g kg-1 agavin promoted the growth of the potentially beneficial families Sphingomonadaceae, Oxalobacteriaceae, and Chitinophagaceae; at high densities, reduced the abundance of pathogenic families (Vibrionaceae and Aeromonadaceae). These results suggest that, under stress conditions, agavin can stimulate the growth of potentially beneficial bacteria and reduce the growth of potentially pathogenic bacteria, suggesting its potential use as a prebiotic in aquaculture.


Assuntos
Ração Animal , Bactérias , Ciclídeos , Suplementos Nutricionais , Frutanos , Microbioma Gastrointestinal , Animais , Microbioma Gastrointestinal/efeitos dos fármacos , Ciclídeos/microbiologia , Ciclídeos/crescimento & desenvolvimento , Ração Animal/análise , Frutanos/farmacologia , Frutanos/metabolismo , Bactérias/classificação , Bactérias/genética , Bactérias/isolamento & purificação , Bactérias/efeitos dos fármacos , Dieta/veterinária , Prebióticos/administração & dosagem , Sequenciamento de Nucleotídeos em Larga Escala
7.
Pharmacogenet Genomics ; 34(9): 285-290, 2024 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-39356102

RESUMO

AIMS: To investigate the association of CYP2C9 metabolic phenotypes with phenytoin plasma concentration ([PTH]) in neurosurgical patients from the Brazilian Public Health System. METHODS: Patients (n = 170) were treated with phenytoin (300 mg/day) perioperatively as prophylaxis for postoperative seizures. Two to 10 days after surgery, a blood sample was collected for quantification of [PTH] and genotyping of CYP2C9*2 and *3 alleles. CYP2C9 metabolic phenotypes, NM (normal), IM (intermediate), and PM (poor) metabolizer, were inferred from CYP2C9 diplotypes. Linear regression modeling was applied to identify predictors of [PTH]. RESULTS: Wide (22-fold) interindividual variation in [PTH] was observed (2.2-47.5 mg/l). [PTH] associated significantly (Kruskal-Wallis P < 0.005) with CYP2C9 phenotypes and there was a significant trend (Jonckheere-Terpstra test, P < 0.0001) for [PTH] increase in the order NM < IM < PM. [PTH] was within the target therapeutic range (10-20 mg/l) in 34.7% of patients, while 39.4% and 25.9% had [PTH] below and above the range, respectively. CYP2C9 phenotypes associated significantly (chi-square P = 0.004) with the distribution of patients in [PHT] therapeutic categories and the Cramér's V test pointed to moderate magnitude of the effect of CYP2C9 phenotypes (V = 0.211). CONCLUSION: Diplotype-predicted CYP2C9 metabolic phenotypes are associated significantly with [PTH] in neurosurgical Brazilian patients receiving phenytoin for postsurgery seizure prophylaxis. [PHT] increased progressively in the phenotype order NM < IM < PM, and all PM patients had [PHT] above the target therapeutic range, consistent with the CPIC guideline 'strong' recommendation for phenytoin dosing adjustments in PMs.


Assuntos
Anticonvulsivantes , Citocromo P-450 CYP2C9 , Fenótipo , Fenitoína , Humanos , Citocromo P-450 CYP2C9/genética , Fenitoína/sangue , Fenitoína/administração & dosagem , Fenitoína/farmacocinética , Brasil , Feminino , Masculino , Adulto , Pessoa de Meia-Idade , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/sangue , Anticonvulsivantes/administração & dosagem , Idoso , Convulsões/tratamento farmacológico , Convulsões/genética , Procedimentos Neurocirúrgicos/efeitos adversos , Adolescente , Genótipo , Adulto Jovem
8.
Rev Bras Epidemiol ; 27: e240044, 2024.
Artigo em Inglês, Português | MEDLINE | ID: mdl-39356893

RESUMO

OBJECTIVE: To evaluate the frequency, reasons and factors associated with intentional nonadherence to drug therapy. METHODS: A population-based cross-sectional study was conducted with data from the National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM). The questionnaire consisted of sociodemographic questions, presence of chronic diseases, medication use, self-rated health, and medication use behaviors. Data analysis included Poisson regression models adjusted for variance. RESULTS: A total of 31,573 individuals were included, most of whom were women (53.8%), with low level of education (57.7%), and self-rated good health (56.5%). Of those interviewed, 8.8% reported increasing the medication dose and 21.2% reported reducing it. The most common reason for dose reduction was the adverse effects of the medication. There were no differences in the reasons for increasing doses. Increasing or reducing doses were most commonly reported by younger people, with lower per capita income and worse self-rated health. CONCLUSION: A considerable portion of the respondents did not intentionally adhere to drug therapy. Understanding nonadherence and identifying those who practice it is crucial for creating effective strategies that promote adherence to treatment and prioritize patients' needs and perspectives.


Assuntos
Adesão à Medicação , Humanos , Feminino , Masculino , Estudos Transversais , Adesão à Medicação/estatística & dados numéricos , Pessoa de Meia-Idade , Adulto , Adulto Jovem , Adolescente , Idoso , Brasil , Fatores Socioeconômicos , Prevalência , Medicamentos sob Prescrição/administração & dosagem
9.
Trop Anim Health Prod ; 56(8): 319, 2024 Oct 02.
Artigo em Inglês | MEDLINE | ID: mdl-39358665

RESUMO

The present study aimed to investigate the impact of adding two doses of a commercial probiotic on productive performance, ruminal and fecal microbiome in growing lambs. Forty-two Texel or Ile de France crossbred lambs aged 86.9 ± 8.0 days (body weight: 27.4 ± 3.7 kg) were distributed into three groups: basal diet without probiotic supplementation (CG); basal diet + 1 g/animal/day of probiotic (GP1) and basal diet + 5 g/animal/day of probiotic (GP5). The experimental period was 84 days. The weight was evaluated weekly and dry matter intake (DMI) and leftovers were measured daily. At the end of the experiment, lambs were slaughtered. Feces and rumen fluid were collected for microbiome analysis and rumen fragments for histological evaluation. The use of probiotics did not affect weight gain, but GP1 showed a higher silage and DMI intake than CG (p < 0.001). The CG had a greater thickness of keratinized epithelium and stratum corneum (< 0.001) than GP1 and GP5, and greater total papilla width (p = 0.039) than GP1. There was no difference in the general abundance in the rumen and fecal microbiomes. GP5 had a higher proportion of Azoarcus and Dialister taxa in the rumen fluid (p = 0.012 and p = 0.017, respectively) and higher proportion of Treponema and Fibrobacter taxa in the fecal microbiome (p = 0.015 and p = 0.026, respectively), whereas CG had a higher proportion of Anaeroplasma than the other groups (p = 0.032). These results demonstrated the benefits of probiotics for ruminal epithelium protection and microbial diversity. However, there was no effect on performance parameters.


Assuntos
Ração Animal , Dieta , Suplementos Nutricionais , Fezes , Microbioma Gastrointestinal , Probióticos , Rúmen , Carneiro Doméstico , Animais , Rúmen/microbiologia , Probióticos/administração & dosagem , Probióticos/farmacologia , Fezes/microbiologia , Ração Animal/análise , Dieta/veterinária , Microbioma Gastrointestinal/efeitos dos fármacos , Carneiro Doméstico/microbiologia , Suplementos Nutricionais/análise , Masculino , Fenômenos Fisiológicos da Nutrição Animal , Ovinos
10.
MMWR Morb Mortal Wkly Rep ; 73(39): 861-868, 2024 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-39361525

RESUMO

To reduce influenza-associated morbidity and mortality, countries in South America recommend annual influenza vaccination for persons at high risk for severe influenza illness, including young children, persons with preexisting health conditions, and older adults. Interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries can provide early information about the protective effects of vaccination and help guide Northern Hemisphere countries in advance of their season. Using data from a multicountry network, investigators estimated interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalization using a test-negative case-control design. During March 13-July 19, 2024, Argentina, Brazil, Chile, Paraguay, and Uruguay identified 11,751 influenza-associated SARI cases; on average, 21.3% of patients were vaccinated against influenza, and the adjusted VE against hospitalization was 34.5%. The adjusted VE against the predominating subtype A(H3N2) was 36.5% and against A(H1N1)pdm09 was 37.1%. These interim VE estimates suggest that although the proportion of hospitalized patients who were vaccinated was modest, vaccination with the Southern Hemisphere influenza vaccine significantly lowered the risk for hospitalization. Northern Hemisphere countries should, therefore, anticipate the need for robust influenza vaccination campaigns and early antiviral treatment to achieve optimal protection against influenza-associated complications.


Assuntos
Hospitalização , Vírus da Influenza A Subtipo H1N1 , Vacinas contra Influenza , Influenza Humana , Eficácia de Vacinas , Humanos , Influenza Humana/prevenção & controle , Influenza Humana/epidemiologia , Vacinas contra Influenza/administração & dosagem , Hospitalização/estatística & dados numéricos , Idoso , Pessoa de Meia-Idade , Adulto , Adolescente , Adulto Jovem , Pré-Escolar , Criança , Eficácia de Vacinas/estatística & dados numéricos , Lactente , América do Sul/epidemiologia , Vírus da Influenza A Subtipo H1N1/isolamento & purificação , Vírus da Influenza A Subtipo H1N1/imunologia , Vírus da Influenza A Subtipo H3N2/isolamento & purificação , Vírus da Influenza A Subtipo H3N2/imunologia , Feminino , Masculino , Estudos de Casos e Controles
11.
Sci Rep ; 14(1): 22979, 2024 10 03.
Artigo em Inglês | MEDLINE | ID: mdl-39362955

RESUMO

One of the measures for monitoring microbial resistance is the calculation of the defined daily dose of antimicrobial agents. For this calculation, the weight of an adult of 70 kg is used as a standard, so that application in neonatology is not possible. The aim of this study is to describe the use profile and calculate the defined daily dose (DDD) of antimicrobials in a neonatal intensive care unit (NICU) of a public hospital in the interior of Bahia, Brazil. From March 2020 to December 2021, the medical records of 712 newborns admitted to a NICU between September 2018 and June 2020 were analyzed. A total of 410 newborns diagnosed with neonatal sepsis were included. The most used antimicrobials per patient were gentamicin (408/410; 99.5%), ampicillin (407; 99.3%), amikacin (29; 7.1%) and oxacillin (21; 5.1%), with a mean (SD) treatment duration of 9.8 (3.9) days. The most commonly used combination of antimicrobials was ampicillin with gentamicin, which was used in 406 patients (99.0%). The values for neonatal DDDs were on average 26 times lower than those for adult DDDs. The neonatal DDDs were similar to those observed in other studies. Ampicilin and cefepime were the antimicrobials for which the greatest differences were observed in neonatal DDDs compared with adult DDDs, which differed mainly between maintenance doses, reflecting the lack of international standards in neonatology. Standardization of DDDs as a surveillance measure has the potential to clarify the pattern of antimicrobial use in neonatal patients worldwide and, in particular, to prevent indiscriminate use and bacterial resistance.


Assuntos
Antibacterianos , Unidades de Terapia Intensiva Neonatal , Neonatologia , Humanos , Recém-Nascido , Neonatologia/métodos , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Feminino , Masculino , Brasil , Gentamicinas/administração & dosagem , Gentamicinas/uso terapêutico , Sepse Neonatal/tratamento farmacológico , Sepse Neonatal/microbiologia , Ampicilina/administração & dosagem , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/uso terapêutico , Amicacina/administração & dosagem , Amicacina/uso terapêutico , Estudos Retrospectivos
12.
J Diet Suppl ; 21(6): 868-880, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39385595

RESUMO

BACKGROUND: Citrulline malate (CM), especially when used in conjunction with physical exercise, has demonstrated potential as a non-pharmacological adjunct in the management of hypertension. Nevertheless, its impact on nocturnal blood pressure dipping remains unexplored. OBJECTIVE: Evaluate the impact of a single dose of CM on nocturnal blood pressure dipping after exercise in hypertensive individuals. METHODS: In a double-blind, placebo-controlled, parallel-group clinical trial, twenty hypertensive adults (55 ± 16 years) were randomly assigned to either a CM (6 g) or placebo (6 g of corn starch) group (PLA). Resting blood pressure was measured after a 20-min period of comfortable seating in a calm environment. Both groups underwent 40 min of treadmill running/walking at an intensity of 60-70% of their reserve heart rate, 120 min after ingesting the substances. Ambulatory blood pressure monitoring was employed to measure blood pressure over 24 h. RESULTS: No significant differences in systolic blood pressure values were observed between the CM and PLA groups at rest, during wakefulness, sleep, or over a 24-h period. However, CM exhibited a significant reduction in diastolic blood pressure in several metrics: delta 24 h (-14 mmHg vs -6 mmHg, p = 0.047), delta wakefulness (-12 mmHg vs -4 mmHg, p = 0.024), percent delta 24 h (-16% vs -6%, p = 0.024), and percent delta wakefulness (-14% vs -4%, p = 0.013). No significant differences were found between CM and PLA in terms of systolic and diastolic nocturnal absolute reductions (-13 mmHg vs -12 mmHg, p = 0.808, and -13 mmHg vs -8 mmHg, p = 0.273, respectively) or nocturnal percentage decrease (-9.9% vs -9.4%, p = 0.844, and -15.3% vs -11.7%, p = 0.399, respectively). CONCLUSIONS: The study found no significant changes in the post-exercise nocturnal blood pressure dip following a single dose of CM supplementation. However, a notable reduction in diastolic blood pressure was observed during the waking period and over the average 24-h monitoring period. CLINICAL TRIAL REGISTRY NUMBER AND WEBSITE: ClinicalTrials.gov platform (NCT03378596).


Assuntos
Monitorização Ambulatorial da Pressão Arterial , Pressão Sanguínea , Citrulina , Suplementos Nutricionais , Exercício Físico , Hipertensão , Malatos , Humanos , Pessoa de Meia-Idade , Citrulina/farmacologia , Citrulina/administração & dosagem , Citrulina/análogos & derivados , Método Duplo-Cego , Masculino , Feminino , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Hipertensão/terapia , Pressão Sanguínea/efeitos dos fármacos , Idoso , Malatos/administração & dosagem , Adulto , Ritmo Circadiano , Frequência Cardíaca/efeitos dos fármacos , Sono/efeitos dos fármacos
13.
Artigo em Inglês | MEDLINE | ID: mdl-39380592

RESUMO

Objective: To compare outcomes in patients with repeated implantation failure undergoing Intracytoplasmic Sperm Injection/In vitro fertilization (IVF/ICSI) plus immunosuppressants such as prednisolone, prednisone, or cyclosporine A versus the use of IVF/ICSI alone. Data source: Databases were systematically searched in PubMed, Cochrane, and Embase databases in September 2023. Study Selection: Randomized clinical trials and observational studies with the outcomes of interest were included. Data collect: We computed odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs). Heterogeneity was assessed using I2 statistics. Data were analyzed using Review Manager 5.4.The main outcomes were live birth, miscarriage, implantation rate, clinical pregnancy, and biochemical pregnancy. Data synthesis: Seven studies with 2,829 patients were included. Immunosuppressive treatments were used in 1,312 (46.37%). Cyclosporine A improved implantation rate (OR 1.48; 95% CI 1.01-2.18) and clinical pregnancy (1.89, 95% CI 1.14-3.14). Compared to non-immunosuppressive treatment, prednisolone and prednisone did not improve live birth (OR 1.13, 95% CI 0.88-1.46) and miscarriage (OR 1.49, 95% CI 1.07-2.09). Prednisolone showed no significant effect in patients undergoing IVF/ICSI, clinical pregnancy (OR 1.34; 95% CI 0.76-2.36), or implantation rate (OR 1.36; 95% CI 0.76-2.42). Conclusion: Cyclosporine A may promote implantation and clinical pregnancy rates. However, given the limited sample size, it is important to approach these findings with caution. Our results indicate that prednisolone and prednisone do not have any beneficial effects on clinical outcomes of IVF/ICSI patients with repeated implantation failure. PROSPERO: CRD42023449655.


Assuntos
Implantação do Embrião , Imunossupressores , Técnicas de Reprodução Assistida , Feminino , Humanos , Gravidez , Ciclosporina/administração & dosagem , Implantação do Embrião/efeitos dos fármacos , Implantação do Embrião/imunologia , Imunossupressores/administração & dosagem , Prednisolona/administração & dosagem , Prednisona/administração & dosagem , Taxa de Gravidez , Injeções de Esperma Intracitoplásmicas
14.
Pharmacol Res Perspect ; 12(5): e70019, 2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39400516

RESUMO

Sarcopenia is characterized by a decline in muscle strength, generalized loss of skeletal muscle mass, and impaired physical performance, which are common outcomes used to screen, diagnose, and determine severity of sarcopenia in older adults. These outcomes are associated with poor quality of life, increased risk of falls, hospitalization, and mortality in this population. The development of sarcopenia is underpinned by aging, but other factors can lead to sarcopenia, such as chronic diseases, physical inactivity, inadequate dietary energy intake, and reduced protein intake (nutrition-related sarcopenia), leading to an imbalance between muscle protein synthesis and muscle protein breakdown. Protein digestion and absorption are also modified with age, as well as the reduced capacity of metabolizing protein, hindering older adults from achieving ideal protein consumption (i.e., 1-1.5 g/kg/day). Nutritional supplement strategies, like animal (i.e., whey protein) and plant-based protein, leucine, and creatine have been shown to play a significant role in improving outcomes related to sarcopenia. However, the impact of other supplements (e.g., branched-chain amino acids, isolated amino acids, and omega-3) on sarcopenia and related outcomes remain unclear. This narrative review will discuss the evidence of the impact of these nutritional strategies on sarcopenia outcomes in older adults.


Assuntos
Suplementos Nutricionais , Sarcopenia , Humanos , Sarcopenia/dietoterapia , Sarcopenia/prevenção & controle , Sarcopenia/metabolismo , Idoso , Músculo Esquelético/metabolismo , Envelhecimento/fisiologia , Proteínas Alimentares/administração & dosagem , Força Muscular , Qualidade de Vida , Idoso de 80 Anos ou mais , Proteínas Musculares/metabolismo
15.
Nutrients ; 16(19)2024 Sep 29.
Artigo em Inglês | MEDLINE | ID: mdl-39408270

RESUMO

Zinc plays a crucial role in cell structure and functionality. Neurodegenerative Duchenne muscular dystrophy (DMD) alters muscle membrane structure, leading to a loss of muscle mass and strength. The objective of this study was to evaluate the changes in phase angle (PA) and bioelectrical impedance vector analysis (BIVA) results in patients with DMD after oral zinc supplementation. This clinical trial included 33 boys aged 5.6 to 24.5 years diagnosed with DMD. They were divided into three groups according to age (G1, G2, and G3) and supplemented with oral zinc. The mean serum zinc concentration was 74 µg/dL, and 29% of patients had concentrations below the reference value. The baseline values (mean (standard deviation)) of the bioelectrical impedance parameters PA, resistance (R), and reactance (Xc) were 2.59° (0.84°), 924.36 (212.31) Ω, and 39.64 (8.41) Ω, respectively. An increase in R and a decrease in PA and lean mass proportional to age were observed, along with a negative correlation (r = -0.614; p < 0.001) between age and PA. The average cell mass in G1 was greater than that in G3 (p = 0.012). There were no significant differences in serum zinc levels or bioelectrical impedance parameters before and after zinc supplementation. We conclude that this population is at risk of zinc deficiency and the proposed dosage of zinc supplementation was not sufficient to alter serum zinc levels, PA and BIVA results.


Assuntos
Suplementos Nutricionais , Impedância Elétrica , Distrofia Muscular de Duchenne , Zinco , Humanos , Distrofia Muscular de Duchenne/tratamento farmacológico , Zinco/administração & dosagem , Zinco/sangue , Zinco/deficiência , Masculino , Adolescente , Criança , Adulto Jovem , Pré-Escolar , Composição Corporal/efeitos dos fármacos , Administração Oral , Músculo Esquelético/efeitos dos fármacos
16.
Nutrients ; 16(19)2024 Oct 08.
Artigo em Inglês | MEDLINE | ID: mdl-39408370

RESUMO

BACKGROUND/OBJECTIVES: The oral administration of hydrolyzed collagen peptides is a scientifically validated intervention for enhancing skeletal muscle health and performance. This integrative review consolidates the evidence supporting the use of low molecular weight collagen peptides (2000-3500 daltons) for their superior bioavailability and absorption. Our objective was to review the effects of collagen peptide or hydrolyzed collagen supplementation on muscle damage, recovery, and construction related to physical exercise. METHODS: A bibliographic search was conducted in major English-language databases, including PubMed/Medline, using terms like "Peptides Collagen and Damage" and "collagen peptides AND Soreness Muscle". This review followed PRISMA guidelines, with bias risk assessed via the PEDro scale. The inclusion criteria were (a) randomized clinical trials, (b) randomized studies in humans with a control or placebo group, (c) studies assessing muscle damage or delayed onset muscle soreness via physiological markers or strength performance tests, and (d) studies using hydrolyzed collagen or collagen peptides. RESULTS: Initially, 752 articles were identified. After applying the inclusion and exclusion criteria, including duplicate removal, eight articles with 286 participants were included. Of these, 130 participants received collagen peptide supplementation, while 171 received a placebo or control. CONCLUSION: This integrative review supports the potential of collagen peptide supplementation to mitigate muscle stress from acute strenuous resistance training. However, due to the methodological heterogeneity among the studies, further clinical trials are needed to clarify the mechanisms underlying muscle improvement with collagen supplementation.


Assuntos
Colágeno , Suplementos Nutricionais , Músculo Esquelético , Mialgia , Humanos , Músculo Esquelético/efeitos dos fármacos , Mialgia/tratamento farmacológico , Peptídeos/farmacologia , Peptídeos/administração & dosagem , Treinamento Resistido , Fadiga Muscular/efeitos dos fármacos , Ensaios Clínicos Controlados Aleatórios como Assunto , Força Muscular/efeitos dos fármacos , Masculino , Adulto , Feminino , Exercício Físico
17.
Nutrients ; 16(19)2024 Oct 08.
Artigo em Inglês | MEDLINE | ID: mdl-39408371

RESUMO

Abundant information exists on fluoride intake and excretion in populations exposed to fluoridated water, but not fluoridated salt, where fluoride is eaten through a combination of foods and beverages. This study assessed associations between dietary patterns, fluoride intake and excretion in Mexican women exposed to fluoridated salt. We estimated dietary fluoride intake and excretion (mg/day) from 31 women using 24-h recalls (ASA24) and 24-h urine collections (HDMS diffusion method) and assessed agreement among both estimates of exposure with a Bland-Altman plot. Dietary patterns among the sample were explored by Principal Component Analysis and associations between these patterns and both fluoride intake and excretion were estimated. using Quantile Regressions. Median dietary fluoride intake and excretion were 0.95 and 0.90 mg/day, respectively, with better agreement at values below 1.5 mg/day. We identified three dietary patterns: "Urban Convenience", "Plant-based" and "Egg-based". The "Urban Convenience" pattern, characterized by dairy and convenience foods was associated with an increase of 0.25 mg and 0.34 mg of F in the 25th and 50th percentiles of intake respectively, (p < 0.01), and a marginal 0.22 mg decrease in urinary fluoride (p = 0.06). In conclusion, in this sample of Mexican women, a dietary pattern rich in dairy and convenience foods, was associated with both fluoride intake and excretion.


Assuntos
Dieta , Fluoretação , Fluoretos , Cloreto de Sódio na Dieta , Humanos , Feminino , Adulto , Fluoretos/urina , Fluoretos/administração & dosagem , México , Cloreto de Sódio na Dieta/administração & dosagem , Dieta/estatística & dados numéricos , Pessoa de Meia-Idade , Adulto Jovem , Comportamento Alimentar , Padrões Dietéticos
18.
Int J Mol Sci ; 25(19)2024 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-39408866

RESUMO

Cancer therapy is constantly evolving, with a growing emphasis on targeted and efficient treatment options. In this context, graphene quantum dots (GQDs) have emerged as promising agents for precise drug and gene delivery due to their unique attributes, such as high surface area, photoluminescence, up-conversion photoluminescence, and biocompatibility. GQDs can damage cancer cells and exhibit intrinsic photothermal conversion and singlet oxygen generation efficiency under specific light irradiation, enhancing their effectiveness. They serve as direct therapeutic agents and versatile drug delivery platforms capable of being easily functionalized with various targeting molecules and therapeutic agents. However, challenges such as achieving uniform size and morphology, precise bandgap engineering, and scalability, along with minimizing cytotoxicity and the environmental impact of their production, must be addressed. Additionally, there is a need for a more comprehensive understanding of cellular mechanisms and drug release processes, as well as improved purification methods. Integrating GQDs into existing drug delivery systems enhances the efficacy of traditional treatments, offering more efficient and less invasive options for cancer patients. This review highlights the transformative potential of GQDs in cancer therapy while acknowledging the challenges that researchers must overcome for broader application.


Assuntos
Sistemas de Liberação de Medicamentos , Técnicas de Transferência de Genes , Grafite , Neoplasias , Pontos Quânticos , Pontos Quânticos/química , Grafite/química , Humanos , Neoplasias/terapia , Neoplasias/tratamento farmacológico , Neoplasias/genética , Sistemas de Liberação de Medicamentos/métodos , Carbono/química , Animais , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Antineoplásicos/administração & dosagem , Antineoplásicos/química
19.
J Med Microbiol ; 73(10)2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39392377

RESUMO

Introduction. Tissue conditioners modified with antifungals are a potential alternative to denture stomatitis (DS) treatment.Gap Statement. Information on tissue response to this treatment before its clinical application is lacking.Aim. This study aimed to evaluate the tissue response of a tissue conditioner modified with antifungals in a rat model of DS.Methodology. After DS induction for 4 days under antibiotic therapy, Wistar rats had their intraoral devices (IODs) relined with the tissue conditioner Softone without (Soft) or with the MICs against Candida albicans of nystatin (Nys) or chlorhexidine (Chx) complexed or not with ß-cyclodextrin (Nys:ßCD and Chx:ßCD). Three controls were included: healthy rats [negative control (Nc)], rats using a sterile IOD [sterile device (Sd)] and rats with DS that did not receive treatment (DS). After 4 days of treatment, the palatal mucosa under the IODs underwent histological processing for morphohistopathological and histometric analyses, morphology of collagen fibres (birefringence), immunohistochemistry for the expression of cell proliferation (proliferating cell nuclear antigen) and cytokine (IL-1ß).Results. The Nc and Sd groups were similar (P>0.05), displaying epithelial and connective tissues without any discernible changes in the parameters assessed. The DS and Soft groups exhibited pronounced epithelial alterations, cell proliferation and expression of the cytokine IL-1ß. In groups treated with drug incorporation (Nys, Chx, Nys:ßCD and Chx:ßCD), all samples demonstrated a reduction in tissue inflammation or complete tissue recovery, with an epithelium compatible with health. For the immunohistochemical parameters, the Chx, Nys:ßCD and Chx:ßCD groups were comparable with Nc (P>0.05).Conclusion. The proposed treatment could be promising for DS, as it led to the tissue recovery of the palatal mucosa. Nevertheless, much lower concentrations of complexed antifungals were required to achieve a similar or higher degree of tissue response compared with uncomplexed drugs in a modified tissue conditioner formulation.


Assuntos
Antifúngicos , Candida albicans , Modelos Animais de Doenças , Mucosa Bucal , Nistatina , Ratos Wistar , Estomatite sob Prótese , beta-Ciclodextrinas , Animais , beta-Ciclodextrinas/química , Antifúngicos/farmacologia , Estomatite sob Prótese/tratamento farmacológico , Estomatite sob Prótese/microbiologia , Ratos , Nistatina/farmacologia , Nistatina/administração & dosagem , Candida albicans/efeitos dos fármacos , Mucosa Bucal/efeitos dos fármacos , Mucosa Bucal/microbiologia , Masculino , Clorexidina/farmacologia , Interleucina-1beta/metabolismo , Antígeno Nuclear de Célula em Proliferação/metabolismo , Testes de Sensibilidade Microbiana
20.
Value Health Reg Issues ; 44: 101014, 2024 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-39368195

RESUMO

OBJECTIVE: This study aimed to evaluate the cost-effectiveness (CE) of minimally invasive interventions for pain associated with articular temporomandibular dysfunction from the Brazilian Public Health System (SUS) perspective. METHODS: This is a CE study with a 1-year time horizon. Effectiveness data were extracted from a network meta-analysis, and 2 treatments with moderate levels of evidence certainty were evaluated: arthrocentesis (ARTRO) plus intra-articular corticosteroid (CO) injection and ARTRO plus intra-articular injection of sodium hyaluronate (SH). For CE analysis, the costs of 2 types of SH (low and high molecular weight) and 4 COs (betamethasone [B], dexamethasone acetate [D], methylprednisolone sodium succinate [M], or triamcinolone hexacetonide [T]) were considered. Modeling was conducted using TreeAge Pro Healthcare software, with the construction of a decision tree representing a hypothetical cohort of adults with articular temporomandibular dysfunction. Deterministic and probabilistic sensitivity analyses were performed. In addition, an acceptability curve was developed. RESULTS: The total costs per joint for ARTRO plus low- and high-molecular-weight SH and ARTRO plus COs B, D, M, and T were, respectively, R$583.32, R$763.85, R$164.39, R$133.93, R$138.57, and R$159.86. ARTRO plus dexamethasone acetate was considered cost-effective, with lower cost and higher net monetary benefit than other technologies. In all sensitivity analysis scenarios, it remained cost-effective. It also showed greater acceptability. CONCLUSION: ARTRO plus dexamethasone acetate was considered the cost-effective technology, exhibiting higher net monetary benefit and higher acceptability from the SUS perspective.


Assuntos
Análise Custo-Benefício , Humanos , Análise Custo-Benefício/métodos , Análise Custo-Benefício/estatística & dados numéricos , Brasil , Injeções Intra-Articulares/economia , Artrocentese/métodos , Artrocentese/economia , Transtornos da Articulação Temporomandibular/tratamento farmacológico , Transtornos da Articulação Temporomandibular/terapia , Transtornos da Articulação Temporomandibular/economia , Ácido Hialurônico/economia , Ácido Hialurônico/administração & dosagem , Ácido Hialurônico/uso terapêutico , Ácido Hialurônico/análogos & derivados , Corticosteroides/uso terapêutico , Corticosteroides/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA